{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:04:38Z","timestamp":1789880678910,"version":"4.0.1"},"posted":{"date-parts":[[2026,9,16]]},"group-title":"Neuroscience","reference-count":53,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["25AARG-1411078"],"award-info":[{"award-number":["25AARG-1411078"]}],"id":[{"id":"https:\/\/ror.org\/0375f4d26","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Kennards Hire Foundation"},{"name":"Bluesand Foundation"},{"name":"NIH","award":["U24NS141774"],"award-info":[{"award-number":["U24NS141774"]}]},{"name":"NIH","award":["P30AG066512"],"award-info":[{"award-number":["P30AG066512"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Biomarkers of cerebral amyloid angiopathy (CAA) are critically needed. We recently identified semaphorin 3G (SEMA3G) as a novel protein selectively enriched in CAA. Here, we aimed to determine if SEMA3G was a selective marker of CAA in a large cohort of human brain tissue spanning multiple neurodegenerative diseases and three brain regions, and to determine if SEMA3G directly interacts with amyloid beta (A\u03b2). Multiplexed immunofluorescence showed that SEMA3G significantly accumulated only in CAA\n                  <jats:sup>+<\/jats:sup>\n                  blood vessels in the brain in all cases. We also showed that SEMA3G preferentially associated with A\u03b2\n                  <jats:sub>40<\/jats:sub>\n                  , A\u03b2\n                  <jats:sub>pS8<\/jats:sub>\n                  and A\u03b2\n                  <jats:sub>pE3,<\/jats:sub>\n                  but not A\u03b2\n                  <jats:sub>42<\/jats:sub>\n                  . Thioflavin T assays and transmission electron microscopy showed that SEMA3G directly interacted with A\u03b2 and slowed A\u03b2 aggregation\n                  <jats:italic>in vitro<\/jats:italic>\n                  , and that this effect was more pronounced for A\u03b2\n                  <jats:sub>40<\/jats:sub>\n                  than A\u03b2\n                  <jats:sub>42<\/jats:sub>\n                  . Together our results demonstrate that SEMA3G is a highly specific marker of CAA in the brain.\n                <\/jats:p>","DOI":"10.64898\/2026.09.10.750803","type":"posted-content","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:30:31Z","timestamp":1789619431000},"source":"Crossref","is-referenced-by-count":0,"title":["Semaphorin 3G (SEMA3G) is a highly selective marker of cerebral amyloid angiopathy"],"prefix":"10.64898","author":[{"given":"Kaleah","family":"Balcomb","sequence":"first","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Buchanan","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysha","family":"Strobbe","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Claus","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arline","family":"Faustin","sequence":"additional","affiliation":[{"name":"Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York University, New York, NY, 10016, USA"},{"name":"Department of Pathology, New York University Grossman School of Medicine, New York, NY, 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Schneider","sequence":"additional","affiliation":[{"name":"Rush Alzheimer\u2019s Disease Center, Rush University Medical Center, 1750 W Harrison Street, Suite 1000, Chicago, IL, 60612, USA"},{"name":"Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA"},{"name":"Department of Pathology, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York University, New York, NY, 10016, USA"},{"name":"Department of Pathology, New York University Grossman School of Medicine, New York, NY, 10016, USA"},{"name":"Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Sunde","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5466-4609","authenticated-orcid":false,"given":"Eleanor","family":"Drummond","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026091921300597000_2026.09.10.750803v1.1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMra2411298","article-title":"Cerebral Amyloid Angiopathy","volume":"394","year":"2026","journal-title":"The New England journal of medicine"},{"key":"2026091921300597000_2026.09.10.750803v1.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2010.01137.x"},{"key":"2026091921300597000_2026.09.10.750803v1.3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300503"},{"key":"2026091921300597000_2026.09.10.750803v1.4","first-page":"19","article-title":"Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue","volume":"3","year":"2014","journal-title":"Am J Neurodegener Dis"},{"key":"2026091921300597000_2026.09.10.750803v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/61.3.282"},{"key":"2026091921300597000_2026.09.10.750803v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70015-7"},{"key":"2026091921300597000_2026.09.10.750803v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"2026091921300597000_2026.09.10.750803v1.8","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.121.036873"},{"key":"2026091921300597000_2026.09.10.750803v1.9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","volume":"82","year":"2025","journal-title":"JAMA neurology"},{"key":"2026091921300597000_2026.09.10.750803v1.10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","year":"2020","journal-title":"Nature reviews. Neurology"},{"key":"2026091921300597000_2026.09.10.750803v1.11","doi-asserted-by":"crossref","first-page":"e71361","DOI":"10.1002\/alz.71361","article-title":"Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer\u2019s disease: An update from the Alzheimer\u2019s Association ARIA workgroup","volume":"22","year":"2026","journal-title":"Alzheimer\u2019s & dementia : the journal of the Alzheimer\u2019s Association"},{"key":"2026091921300597000_2026.09.10.750803v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00208-3"},{"key":"2026091921300597000_2026.09.10.750803v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30006-1"},{"key":"2026091921300597000_2026.09.10.750803v1.14","doi-asserted-by":"crossref","first-page":"e218314","DOI":"10.1212\/WNL.0000000000218314","article-title":"Diagnostic Accuracy of the Boston Criteria v2.0 in Memory Clinic Patients: An MRI-Neuropathology Validation Study","volume":"107","year":"2026","journal-title":"Neurology"},{"key":"2026091921300597000_2026.09.10.750803v1.15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00401-024-02767-1","article-title":"Differences in the cerebral amyloid angiopathy proteome in Alzheimer\u2019s disease and mild cognitive impairment","volume":"148","year":"2024","journal-title":"Acta neuropathologica"},{"key":"2026091921300597000_2026.09.10.750803v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03376-x"},{"key":"2026091921300597000_2026.09.10.750803v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04521-7"},{"key":"2026091921300597000_2026.09.10.750803v1.18","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41467-023-40208-x","article-title":"Compilation of reported protein changes in the brain in Alzheimer\u2019s disease","volume":"14","year":"2023","journal-title":"Nature communications"},{"key":"2026091921300597000_2026.09.10.750803v1.19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s44477-026-00035-y","article-title":"Translating Alzheimer\u2019s disease proteomics into drug discovery opportunities","volume":"2","year":"2026","journal-title":"Molecular Neurodegeneration Advances"},{"key":"2026091921300597000_2026.09.10.750803v1.20","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.215871"},{"key":"2026091921300597000_2026.09.10.750803v1.21","doi-asserted-by":"crossref","first-page":"110613","DOI":"10.1016\/j.cellsig.2023.110613","article-title":"Sema3G activates YAP and promotes VSMCs proliferation and migration via Nrp2\/PlexinA1","volume":"105","year":"2023","journal-title":"Cell Signal"},{"key":"2026091921300597000_2026.09.10.750803v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.12.036"},{"key":"2026091921300597000_2026.09.10.750803v1.23","doi-asserted-by":"crossref","unstructured":"Chen, D.Y. , et al. Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating beta-catenin-dependent vascular remodeling. J Clin Invest 131(2021).","DOI":"10.1172\/JCI135296"},{"key":"2026091921300597000_2026.09.10.750803v1.24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1113\/JP282286","article-title":"Notch1 promotes ordered revascularization through Semaphorin 3g modulation of downstream vascular patterning signalling factors","volume":"600","year":"2022","journal-title":"J Physiol"},{"key":"2026091921300597000_2026.09.10.750803v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2005.00877.x"},{"key":"2026091921300597000_2026.09.10.750803v1.26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2337\/db24-0997","article-title":"Targeting SETD7 Rescues Diabetes-Induced Impairment of Angiogenic Response by Transcriptional Repression of Semaphorin-3G","volume":"74","year":"2025","journal-title":"Diabetes"},{"key":"2026091921300597000_2026.09.10.750803v1.27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s40478-023-01694-8","article-title":"Cryo-EM structures of Abeta40 filaments from the leptomeninges of individuals with Alzheimer\u2019s disease and cerebral amyloid angiopathy","volume":"11","year":"2023","journal-title":"Acta neuropathologica communications"},{"key":"2026091921300597000_2026.09.10.750803v1.28","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/s41418-025-01534-3","article-title":"Endothelial cells-derived SEMA3G suppresses glioblastoma stem cells by inducing c-Myc degradation","volume":"32","year":"2025","journal-title":"Cell death and differentiation"},{"key":"2026091921300597000_2026.09.10.750803v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101259"},{"key":"2026091921300597000_2026.09.10.750803v1.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02911-5"},{"key":"2026091921300597000_2026.09.10.750803v1.31","doi-asserted-by":"crossref","first-page":"e70335","DOI":"10.1111\/jnc.70335","article-title":"Post-Translational Modifications Distinguish Amyloid-beta Isoforms in Cerebral Amyloid Angiopathy and Alzheimer\u2019s Disease","volume":"169","year":"2025","journal-title":"Journal of neurochemistry"},{"key":"2026091921300597000_2026.09.10.750803v1.32","first-page":"452","article-title":"High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy","volume":"145","year":"1994","journal-title":"The American journal of pathology"},{"key":"2026091921300597000_2026.09.10.750803v1.33","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1993.1112"},{"key":"2026091921300597000_2026.09.10.750803v1.34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.13.7013"},{"key":"2026091921300597000_2026.09.10.750803v1.35","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380312"},{"key":"2026091921300597000_2026.09.10.750803v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.02.033"},{"key":"2026091921300597000_2026.09.10.750803v1.37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/acn3.577","article-title":"Modified amyloid variants in pathological subgroups of beta-amyloidosis","volume":"5","year":"2018","journal-title":"Annals of clinical and translational neurology"},{"key":"2026091921300597000_2026.09.10.750803v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(95)90301-1"},{"key":"2026091921300597000_2026.09.10.750803v1.39","doi-asserted-by":"crossref","unstructured":"Koutarapu, S. , et al. Chemical signatures delineate heterogeneous amyloid plaque populations across the Alzheimer\u2019s disease spectrum. bioRxiv (2024).","DOI":"10.1101\/2024.06.03.596890"},{"key":"2026091921300597000_2026.09.10.750803v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.05.005"},{"key":"2026091921300597000_2026.09.10.750803v1.41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt362"},{"key":"2026091921300597000_2026.09.10.750803v1.42","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-004-0822-6"},{"key":"2026091921300597000_2026.09.10.750803v1.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0070-z"},{"key":"2026091921300597000_2026.09.10.750803v1.44","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/s43587-025-00965-4","article-title":"Plasma proteomic associations with Alzheimer\u2019s disease endophenotypes","volume":"5","year":"2025","journal-title":"Nat Aging"},{"key":"2026091921300597000_2026.09.10.750803v1.45","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/alz.13821","article-title":"Proteomic changes in the human cerebrovasculature in Alzheimer\u2019s disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s & dementia : the journal of the Alzheimer\u2019s Association"},{"key":"2026091921300597000_2026.09.10.750803v1.46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40478-023-01698-4","article-title":"Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients","volume":"12","year":"2024","journal-title":"Acta neuropathologica communications"},{"key":"2026091921300597000_2026.09.10.750803v1.47","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.3233\/JAD-179939","article-title":"Religious Orders Study and Rush Memory and Aging Project","volume":"64","year":"2018","journal-title":"Journal of Alzheimer\u2019s disease : JAD"},{"key":"2026091921300597000_2026.09.10.750803v1.48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002175"},{"key":"2026091921300597000_2026.09.10.750803v1.49","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000271090.28148.24"},{"key":"2026091921300597000_2026.09.10.750803v1.50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00401-024-02819-6","article-title":"SMOC1 colocalizes with Alzheimer\u2019s disease neuropathology and delays Abeta aggregation","volume":"148","year":"2024","journal-title":"Acta neuropathologica"},{"key":"2026091921300597000_2026.09.10.750803v1.51","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty355"},{"key":"2026091921300597000_2026.09.10.750803v1.52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063906"},{"key":"2026091921300597000_2026.09.10.750803v1.53","doi-asserted-by":"publisher","DOI":"10.1002\/PRO.3943"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.10.750803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:30:23Z","timestamp":1789878623000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.10.750803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":53,"URL":"https:\/\/doi.org\/10.64898\/2026.09.10.750803","relation":{},"subject":[],"published":{"date-parts":[[2026,9,16]]},"subtype":"preprint"}}